This biotechnology company develops oligonucleotide therapeutics targeting cancer, immunology, and metabolic diseases, focusing on delivering potent drugs to non-liver tissues such as the heart and lungs. By enhancing drug distribution and reducing toxicity, the company aims to improve treatment outcomes for infectious diseases with fewer side effects.
Funding
Funding not disclosed
Founders
Product
Problem
Current oligonucleotide therapeutics face challenges in effectively reaching non-liver tissues, such as the heart and lungs, limiting their efficacy in treating diseases affecting these organs. Existing delivery methods often result in off-target effects and toxicity, hindering the development of safe and potent drugs for various conditions.
Solution
This biotechnology company is developing a novel platform for oligonucleotide therapeutics that enhances drug delivery to non-liver tissues, improving treatment outcomes for diseases like cancer, immunological disorders, and metabolic diseases. Their approach focuses on optimizing drug distribution and minimizing toxicity, enabling the development of more potent clinical leads with fewer side effects. By targeting specific tissues such as the heart and lungs, the company aims to create more effective and safer therapies for a range of conditions. The platform seeks to overcome the limitations of traditional oligonucleotide delivery methods, paving the way for new treatments with improved efficacy and reduced adverse effects.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing oligonucleotide therapeutics for diseases affecting non-liver tissues.
Features
- Enhanced oligonucleotide delivery to non-liver tissues, including the heart and lungs
- Reduced off-target effects and toxicity compared to existing delivery methods
- Optimized drug distribution for improved therapeutic efficacy
- Development of potent clinical leads for cancer, immunology, and metabolic diseases